Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808

Journal of Alzheimer's Disease

Volumn 38, Issue 1, 2014, Pages 171-184

  Chien, David T ^a   Szardenings, A Katrin ^a   Bahri, Shadfar ^b   Walsh, Joseph C ^a   Mu, Fanrong ^a   Xia, Chunfang ^a   Shankle, William R ^c   Lerner, Alan J ^d   Su, Min Ying ^b   Elizarov, Arkadij ^a   Kolb, Hartmuth C ^a  

^a SIEMENS CORPORATE RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hoag Neurosciences Institute   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Alzheimer's disease; amyloid ; brain imaging; mild cognitive impairment; molecular imaging; neurofibrillary tangles; PHF tau; tau; tau aggregates; tauopathy

Indexed keywords

HYPERPHOSPHORYLATED TAU; RADIOLIGAND; T808 F 18; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; ISOTOPE LABELING; MALE; MINI MENTAL STATE EXAMINATION; MOLECULAR IMAGING; NEUROIMAGING; NEUROLOGIC EXAMINATION; PET SCANNER; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; AMYLOID-Β; BRAIN IMAGING; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLES; PHF-TAU; TAU; TAU AGGREGATES; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZIMIDAZOLES; BRAIN; BRAIN MAPPING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; TAU PROTEINS; TIME FACTORS;

EID: 84887230291     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130098     Document Type: Article

References (20)

1. Alzheimer's, Association (2012) Alzheimer's Association Update. Alzheimers Dement 6, 86-88.
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
3. Buchhave P, Minthon L, Zetterberg H, Wallin K, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of fj-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
4. Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, Brooks AF, Kilbourn MR, Albin RL, Frey KA, Scott PJH (2012) Evaluation of [11C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett 3, 936-941.
5. Villemagne V, Furumoto S, Fodero-Tavoletti M, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Oka-muraN (2012) The challenges of tau imaging. Future Neurol 7, 409-421.
6. Watanabe H, Ono M, Kimura H, Matsumura K, Yoshimura M, Okamoto Y, Ihara M, Takahashi R, Saji H (2012) Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett 22, 5700-5703.
7. Villemagne V, Furumoto S, Fodero-Tavoletti M, Mulligan R, Hodges J, Kudo Y, Masters C, Yanai K, Rowe C, Okamura N (2012) In vivo tau imaging in Alzheimer's disease. J Nucl Med 53 (Suppl 1), 36.
8. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34, 457-468.
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immuno-cytochemistry. Acta Neuropathol 112, 389-404. (Pubitemid 44469160)
10. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
11. Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31, 601-612.
12. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
13. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pon-tecorvo MJ (2010) In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [18F]AV-45 (Florbetapir F 18). J Nucl Med 51, 913-920.
14. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, DeKosky S, Mathis CA (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 50, 348-355.
15. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Medical Research Council Cognitive Function, Ageing, Study Age, neuropathology, and dementia. NEngl J Med 360, 2302-2309.
16. Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D (2013) Confirmation of the amyloidogenic process in posterior cortical atrophy: Value of the Afj42/Afj40 ratio. J Alzheimers Dis 33, 775-780.
17. Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, Thomas-Anterion C, Croisile B, Mollion H, Moreaud O, Salzmann M, Dorey A, Bataillard M, Coste MH, Vighetto A, Krolak-Salmon P (2011) CSF biomarkers in posterior cortical atrophy. Neurology 76, 1782-1788.
18. Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, Mercier B, Krolak-Salmon P, Vighetto A (2011) In vivo demonstration of amyloid burden in posterior cortical atrophy: A case series with PET and CSF findings. J Neurol 10, 1841-1851.
19. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehericy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M (2011) Similar amyloid-fj burden in posterior cortical atrophy and Alzheimer's disease. Brain 134, 2036-2043.
20. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knoopman DS, Petersen RC (2004) Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63, 1168-1174. (Pubitemid 39350012)